Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironmentOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study investigated whether Gegen Qinlian decoction (GQD), a traditional Chinese medicine formula already used for ulcerative colitis and type 2 diabetes, could enhance the effectiveness of anti-PD-1 immunotherapy in microsatellite stable (MSS) colorectal cancer. MSS tumors make up most colorectal cancer cases and typically do not respond to PD-1 blockade alone. The researchers combined GQD with anti-mouse PD-1 antibody and evaluated tumor growth, gut microbiota composition, and metabolomic changes. Systemic pharmacology methods were also used to map the multiple targets and pathways through which GQD may act.
Who was studied?
The study used a CT26 xenograft mouse model of colorectal cancer, meaning the findings come from an animal model rather than human patients. The abstract does not specify the number of mice used or additional cohort details. Gut microbiota and metabolomic analyses were performed on samples from these tumor-bearing mice.
What were the most important findings?
Combination therapy with GQD and anti-PD-1 potently inhibited CT26 tumor growth compared to other conditions tested. Gut microbiota analysis showed the combination significantly enriched Bacteroides acidifaciens and an uncultured organism within the Bacteroidales S24-7 group. Metabolomic analysis revealed profoundly altered metabolites in the combination group, with glycerophospholipid metabolism and sphingolipid metabolism identified as key affected signaling pathways. The abstract does not mention Desulfovibrio, sulfate-reducing bacteria, or sulfur metabolism as part of these findings.
What are the greatest implications of this study?
These results suggest that a classical herbal formula can convert an immunologically unresponsive tumor type into one that benefits from checkpoint blockade, by remodeling both the gut microbiota and the tumor microenvironment. The identification of specific bacterial taxa and lipid metabolic pathways offers potential mechanistic targets for future combination immunotherapy strategies. Because this work was conducted in a mouse xenograft model, further studies would be needed to determine whether GQD combined with PD-1 blockade produces similar benefits in human MSS colorectal cancer patients.